Raw material costs stood at 57.7% of the consolidated revenues-higher than the year-ago level of 56.5%. Other expenses, too, climbed to make up 16.2% of the revenues-much higher than the y-o-y level of 14.8%. These increased expenses, and a less favourable product mix, dented profitability.
Sun Pharma deal structurally strong, debt the only overhang: Amit Khurana
Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma’s acquisition is seen as strategically sound, though debt requires careful management.
April 27, 2026